ClinicalTrials.gg
RecruitingNCT06527495Updated Jul 30, 2024

Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma

A Phase 1/2 interventional study of Sorafenib in HCC and Hepatocellular Carcinoma, sponsored by Assiut University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-07-30.

Sponsored by Assiut University · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 6 months after the study started (first participant enrolled Jan 2023, registered Jul 2024).
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies testing sorafenib in Carcinoma, Hepatocellular — 5 open to participants now, 7 under way, 1 of them phase 3. Sorafenib · Carcinoma, Hepatocellular.

Planned enrollment
22nd of 104
150 · median 44
Started
2023
the only one that year
Phase 1/2
13 of 104
2 open now
Registered
104th of 104
by date

Among the 104 studies testing sorafenib in Carcinoma, Hepatocellular, this one is the 22nd largest by planned enrollment, is the only one that started in 2023, is one of 13 in phase 1/2, and was the 104th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

5 of the 104 studies testing sorafenib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About sorafenib

Sorafenib: first FDA approval 2005 (NEXAVAR), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing sorafenib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The current study will aim to maximize the therapeutic effect and to minimize the adverse effects of sorafenib in HCC through pharmacogenomic analysis of VEGFA and KDR genetic polymorphisms.

03

Conditions studied

  • HCC
  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of all studied subjects ≥ 18 years old
  • All patients with hepatocellular carcinoma will be included in group I.
  • Patients not treated with systemic TKIs

Exclusion criteria

Exclusion Criteria:

  • Patients presented with liver tumors other than HCC.
  • Patients with grade C for liver function.
  • Patients with other .
  • Patients with chronic inflammatory disorders.
  • Patients with severe organ dysfunction such as heart, lung, and kidney.
  • Patients who cannot tolerate or are allergic to sorafenib.
  • Patients with severe coagulation dysfunction were uncorrectable.
  • Age less than 18 years old.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Sorafenib

    Sorafenib 200 - 400 mg twice daily

    Drug: Sorafenib

Interventions

  • Sorafenib Tablets (200 -400 mg) twice daily

06

What researchers measure

Primary outcomes

  1. Vascular Endothelial Growth Factor A (VEGFA) genotyping

    Genetic polymorphism of VEGFA

    Time frame: At Baseline, 3 month, and 6 month after treatment.

  2. Kinase insert domain receptor (KDR) genotyping

    Genetic polymorphism of KDR

    Time frame: At Baseline, 3 month, and 6 months after treatment.

Secondary outcomes

  1. Tumor markers

    Determination of serum Alpha-Fetoprotein, AFP-L3

    Time frame: At Baseline, 3 month, and 6 month after treatment.

  2. Complete blood culture

    Determination of hemoglobin concentration

    Time frame: At Baseline 3 month, and 6 months after treatment.

  3. Kidney function tests

    Determination of Serum creatinine concentration

    Time frame: At Baseline 3 month, and 6 months after treatment.

  4. Liver function tests.

    Determine serum level of ALT and AST

    Time frame: At Baseline 3 month, and 6 months after treatment.

  5. Safety outcome

    Incidence of side effects such as (diarrhea, anorexia, nausea, vomiting, hand and foot syndrome)

    Time frame: At Baseline, 3 month, and 6 months after treatment.

07

Study locations

1 of 1 sites recruiting
  • NLI
    Shibīn Al Kawm, Menoufia 32511, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Dec 2024, 23 months after the start.

Of 136 phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 76. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2024
First posted
Jul 30, 2024
StartActual
Jan 1, 2023
Primary completionEst.
Dec 1, 2024
CompletionEst.
Dec 1, 2024
Last update
Jul 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06527495
Lead sponsor
Assiut University
Responsible party
Mahmoud Nazih (Principal Investigator, Assiut University) — Principal investigator
First posted
Jul 30, 2024
Start date
Jan 1, 2023
Primary completion
Dec 1, 2024 (estimated)
Completion
Dec 1, 2024 (estimated)
Last update
Jul 30, 2024

Study contacts

Mahmoud Nazih
Contact
Mahmoud.Nazih5698@pharm.aun.edu.eg
00201093859868

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sorafenib

Start the discussion